JP2017500113A - 生分解性医療用接着剤又はシーラント組成物 - Google Patents
生分解性医療用接着剤又はシーラント組成物 Download PDFInfo
- Publication number
- JP2017500113A JP2017500113A JP2016538741A JP2016538741A JP2017500113A JP 2017500113 A JP2017500113 A JP 2017500113A JP 2016538741 A JP2016538741 A JP 2016538741A JP 2016538741 A JP2016538741 A JP 2016538741A JP 2017500113 A JP2017500113 A JP 2017500113A
- Authority
- JP
- Japan
- Prior art keywords
- oxidized
- sealant composition
- medical adhesive
- component
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 239000000853 adhesive Substances 0.000 title claims abstract description 47
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 47
- 239000000565 sealant Substances 0.000 title claims abstract description 27
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 37
- 229920000768 polyamine Polymers 0.000 claims abstract description 28
- 230000023597 hemostasis Effects 0.000 claims abstract description 18
- 230000002265 prevention Effects 0.000 claims abstract description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 41
- 229920002674 hyaluronan Polymers 0.000 claims description 41
- 229960003160 hyaluronic acid Drugs 0.000 claims description 41
- 230000003647 oxidation Effects 0.000 claims description 19
- 238000007254 oxidation reaction Methods 0.000 claims description 19
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 18
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 18
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 17
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 238000011049 filling Methods 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 8
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 8
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 8
- 108010039918 Polylysine Proteins 0.000 claims description 6
- 229920000656 polylysine Polymers 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 102000007327 Protamines Human genes 0.000 claims description 4
- 108010007568 Protamines Proteins 0.000 claims description 4
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229940048914 protamine Drugs 0.000 claims description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 4
- 229940063673 spermidine Drugs 0.000 claims description 4
- 229940063675 spermine Drugs 0.000 claims description 4
- 229920002567 Chondroitin Polymers 0.000 claims description 2
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 229920000288 Keratan sulfate Polymers 0.000 claims description 2
- 239000005700 Putrescine Substances 0.000 claims description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 2
- 229940051593 dermatan sulfate Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 2
- 238000001879 gelation Methods 0.000 abstract description 25
- 238000010521 absorption reaction Methods 0.000 abstract description 10
- 230000001976 improved effect Effects 0.000 abstract description 4
- 239000011248 coating agent Substances 0.000 abstract description 3
- 238000000576 coating method Methods 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000000499 gel Substances 0.000 description 18
- 208000032843 Hemorrhage Diseases 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000000740 bleeding effect Effects 0.000 description 14
- 239000012153 distilled water Substances 0.000 description 14
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 210000001015 abdomen Anatomy 0.000 description 9
- 239000013466 adhesive and sealant Substances 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229940030225 antihemorrhagics Drugs 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002874 hemostatic agent Substances 0.000 description 5
- 229960003299 ketamine Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000003240 portal vein Anatomy 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 229940050528 albumin Drugs 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 230000002439 hemostatic effect Effects 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 4
- 229960001600 xylazine Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 3
- 229940012189 methyl orange Drugs 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 229920001651 Cyanoacrylate Polymers 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010017788 Gastric haemorrhage Diseases 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000005161 hepatic lobe Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 238000013059 nephrectomy Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229920001351 ε-poly-L-lysine Polymers 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 241000872931 Myoporum sandwicense Species 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000972623 Streptomyces albulus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004830 Super Glue Substances 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010299 mechanically pulverizing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- -1 monosaccharide O-glycoside Chemical class 0.000 description 1
- RPQUGMLCZLGZTG-UHFFFAOYSA-N octyl cyanoacrylate Chemical compound CCCCCCCCOC(=O)C(=C)C#N RPQUGMLCZLGZTG-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/745—Polymers of hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/009—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(a)ホルミル基が導入されて酸化された酸化グリコサミノグリカンを含む第1成分と、
(b)2以上のアミノ基を有するポリアミンを含み、水溶液状態におけるpHが8.5乃至11.0である第2成分と、
を含む生分解性医療用接着剤又はシーラント(又は医療用接着剤又はシーラント組成物)を提供する。
(a)ホルミル基が導入されて酸化された酸化グリコサミノグリカンを含む第1成分と、
(b)2以上のアミノ基を有するポリアミンを含み、水溶液状態におけるpHが8.5乃至11.0である第2成分と、
を含み、前記第1及び第2成分を混合した場合、ホルミル基/アミノ基のモル比は、0.1乃至500である生分解性医療用接着剤又はシーラント(又は医療用接着剤又はシーラント組成物)を提供する。
(i)本発明は、酸化グリコサミノグリカンとポリアミンとを含む生分解性医療用接着剤又はシーラント組成物を提供する。
(ii)本発明の組成物は、生分解性、塗布性、ゲル化時間、止血能、接着力及び水分吸収力などにおいて、改善された効果を示す。
(iii)本発明の組成物は、生体組織の接着、充填、塗布、癒着防止、創傷被覆、漏出防止又は止血など、医療用接着剤又はシーラントが使用可能な多様な医療用途に活用できる。
(1)酸化ヒアルロン酸(CHO−HA;第1成分)の製造
分子量7kDa、150kDa、1400kDaあるいは3000kDaのヒアルロン酸(HA)1g又は3gを過ヨウ素酸ナトリウム(NaIO4)が溶解されている150mlの水に溶かした。この際、過ヨウ素酸ナトリウムの濃度と反応条件を下記表1乃至4のようにして、酸化度(置換度(DS)、%)を異なるようにした。反応フラスコを15〜70℃で3〜48時間反応した。反応物を、蒸留水で分画分子量1〜100kDaの透析膜を利用して24時間透析した。ここで収得した酸化ヒアルロン酸を4日以上凍結乾燥した後、粉砕して500μmサイズのメッシュを通過させることにより、直径約500μm以下の酸化ヒアルロン酸を収得した。
多様なアミノ基含有ポリアミンのうち、代表的にキトサン、プロタミン、PEI、ポリリジン、スペルミン、スペルミジン及びアルブミンなどを第2成分として利用し、5重量%以上のポリアミン水溶液から、pH調節剤(酸、酸塩、塩基、塩基塩など)を利用してpHを8.5、9.0、9.5及び10に調節した後、前記酸化ヒアルロン酸/酸化コンドロイチン硫酸の場合と同様に、凍結乾燥後に収得された粉末を使用した。
(1)ゲル化評価
実施例1で得られた第1及び第2成分を相異なる重量比(1:1、2:1、4:1、8:1)で混合した。混合した成分に水をかけて、ゲル化される程度を確認した。
2mlチューブに混合した成分を30mgずつ小分けし、チューブの蓋に集めた。これに120μlの水を1秒以内にかけた後、ゲル化される時間を測定した。LYDEXの場合は、ヒアルロン酸混合製剤に比べ、少ない量(80μl)の水を適用したにもかかわらず、固まったゲルを得るまで10秒以上が所要された。その反面、酸化ヒアルロン酸の混合製剤の場合は、2〜3秒以内の短いゲル化時間を示した(図4及び表5)。
100mgの混合した成分に800μlの水をかけた後、Texture Analyzerを利用して粘着力を測定した。その結果、LYDEXは、酸化ヒアルロン酸混合製剤に比べて少ない量(500μl)の水を適用したにもかかわらず、平均粘着力が約53.6gfであった。その反面、酸化ヒアルロン酸の混合製剤の場合は、平均粘着力がそれぞれ約65.9及び67.5gfと測定された(図5及び表6)。
LYDEXと、第2成分と混合したそれぞれのCHO−HA 150kDa(DS 10%)、CHO−HA 1,400kDa(DS 10%)の吸収力を評価した。各サンプル30mgをペトリディッシュ(Ф60)にのせて、重量を測定した。予め37℃に温めておいた蒸留水を、製品の吸収力を考慮し、サンプル重量の30倍(30g)を添加した。37℃の恒温器で30分間放置した後、ペトリディッシュを30秒間ひっくり返しておいて、その重量を測定した。下記の計算式を利用して吸収力を計算した。
(1)実験動物
体重2乃至3kgの3匹の雄性ラビット(New Zealand White;オリエントバイオ(Orient Bio),ソンナン,大韓民国)を実験に使用した。全ての動物飼育及び試験過程は、インハ大学校の実験動物研究委員会(Experimental Animal Research Committee)の指針にしたがって行った。
ラビットの粘膜切除(mucosectomy)−誘導胃出血モデルを以下のように制作した。手術前、24時間ラビットを絶食させて、ケタミン(4.2mg/kg)及びシラジン(11.7mg/kg)の混合物を筋肉注射して麻酔した。ラビットの上腹部を切開して胃を露出させて、胃の大湾曲(greater curvature)にそって約5〜7cm程度切開した。等張生理食塩水200μlを胃の粘膜下層(submucosal layer)に注射し、膨潤した胃粘膜を、手術ハサミを使用して切除した。切除された部位の直径は、約7〜10mmであった。
出血されている切除されたラビットの胃粘膜に約0.5gの混合製剤(1:1重量比の第1成分と第2成分との混合物)を塗布した。その結果、図6に示されたように、混合製剤を塗布してからすぐ混合製剤と血液が反応して、混合製剤のゲル化がなされて、非処置群に比べ出血時間が短縮された。また、本発明の組成物の粘膜付着能力を確認した(図6)。
(1)酸化ヒアルロン酸と酸化コンドロイチン硫酸(第1成分)の製造
分子量1,400kDaのヒアルロン酸(SHANDONG BLOOMAGE FREDA BIOPHARM CO.,Ltd)3gを150mlの蒸留水に溶解させた。その後、表1のように過ヨウ素酸ナトリウム(分子量213.89)を添加して、反応フラスコを40℃で24時間攪拌しながら反応した。そして、反応後の溶液を蒸留水で48時間透析(分画分子量12,000〜14,000の透析膜使用)した後、凍結乾燥した。
多様なアミノ基含有ポリアミンのうち、代表的にキトサン、プロタミン、PEI、ポリリジン、スペルミン、スペルミジン及びアルブミンなどを第2成分として選択し、第2成分としては、pHによるゲル化有無を調べるために、水溶液状態でpHを多様な範囲(5.5−6.4,6.5−7.4,7.5−8.4,8.5−9.4,9.5−10.4,10.5−11)に調節した後、前記酸化ヒアルロン酸/酸化コンドロイチン硫酸の場合と同様に、凍結乾燥後に得られた粉末を使用した。前記第1成分の酸化ヒアルロン酸/酸化コンドロイチン硫酸とポリアミンを混合した。その結果、ポリアミンの種類に関係なく、pHが8.5−11である場合にのみ、ゲル化されることを確認した。一例として、ポリ−L−リジンのpHが8.5である場合は、ゲルが形成されたが、pH5.6ではゲルが形成されなかった。本実験においてゲルの形成有無は、ゲルの透明度によって決定した(透明:ゲル化、不透明:非ゲル化)(図7)。
(1)分子量、比率別の最適条件の確立
収得された粉末状の酸化コンドロイチン硫酸と分子量150〜3,000kDaの酸化ヒアルロン酸(1:1)を、酸化度によって比率別にポリアミン(PA;pH8.5−9.5 ポリリジン選定して使用)と混ぜて物性を確認した。酸化度によって比率別に混ぜた50mgに滅菌された蒸留水200μlを入れて、滅菌された蒸留水を吸収するかどうか、目視でその程度を確認した。粉末が、滅菌された蒸留水を10秒以内に吸収し始めた時を良好(+++)、30秒以内を普通(++)、60秒以上を不良(+)と評価し、溶解度(solubility)を確認した。また、滅菌された蒸留水を入れた時、ゲル化されるかどうかを確認し、その時間を測定した。このように形成されたゲルが再び液化されるかどうかを確認し、その時間を測定した。このように確認した結果を下記表にまとめて示した(表10及び11)。
(1)肝葉切除術モデル
体重200〜300gの雄性SDラットの腹腔にケタミンとキシラジン混合物を注射して麻酔した後、中央上腹部を縦又は横に約3〜4cm程度切開した。切開された腹部から、濡れたガーゼを利用して肝葉を露出させて、肝門脈及び肝動脈を血管用クリップで結紮した。肝葉の縁から約1cm程度離れた箇所を、手術用ハサミを利用して切除し、UI−SAH 50〜100mgを塗布した。対照群としては、AristaTM AH(Medafor Inc.,USA)を塗布した。塗布後、結紮していたクリップを除去した後、出血が発生するかどうか確認し、滅菌ガーゼを利用して出血量を測定した。
体重200〜300gの雄性SDラットの腹腔にケタミン及びキシラジンの混合物を注射して麻酔した後、右側腹部を縦に約3〜4cm程度切開した。切開された腹部から、濡れたガーゼを利用して腎臓を露出させて、腎静脈(renal vein)、腎動脈(renal arteries)を血管用クリップで結紮した。腎臓の縁から約1cm程度離れた箇所を、手術用ハサミを利用して切除し、UI−SAH 50〜100mgを塗布した。対照群としては、AristaTM AH(Medafor Inc.,USA)を塗布した。塗布後、結紮していたクリップを除去した後、出血が発生するかどうか確認し、滅菌ガーゼを利用して出血量を測定した。
体重200〜300gの雄性SDラットを24時間絶食させた後、腹腔にケタミン及びキシラジンの混合物を注射して麻酔した後、中央上腹部を縦又は横に約3〜4cm程度切開した。切開された腹部から、濡れたガーゼを利用して胃を露出させて、血管の少ない胃の湾曲部位を水平に約3cm程度切開して、胃内壁が見えるようにした。胃内壁に注射用生理食塩水100μlを注入した後、胃粘膜を手術用ハサミで約5mm直径の円になるように切除し、UI−SAH 50〜100mgを塗布した。対照群としては、AristaTM AH(Medafor Inc.,USA)を塗布した。塗布部位に出血が発生するかどうか確認し、滅菌ガーゼを利用して出血量を測定した。
体重200〜300gの雄性SDラットの腹腔にケタミン及びキシラジンの混合物を注射して麻酔した後、中央上腹部を縦又は横に約5〜6cm程度切開した。切開された腹部から、他の臓器を左側に移動させた後、門脈を露出させた。門脈の上側と下側の2ヶ所を血管用クリップで結紮した。18ゲージ針を利用して門脈に穴をあけた後、UI−SAH 50〜100mgを塗布した。対照群としては、AristaTM AH(Medafor Inc.,USA)を塗布した。塗布後、結紮していたクリップを除去した後、出血が発生するかどうか確認し、滅菌ガーゼを利用して出血量を測定した。
実験結果を、図8乃至12に示した。図12に示したように、本発明の組成物の止血効果は、対照群(AristaTM AH)に比べ、さらに優れていた。
Claims (10)
- (a)ホルミル基が導入されて酸化された酸化グリコサミノグリカンを含む第1成分と、
(b)2以上のアミノ基を有するポリアミンを含み、水溶液状態におけるpHが8.5乃至11.0である第2成分と、
を含むことを特徴とする生分解性医療用接着剤又はシーラント組成物。 - 前記酸化グリコサミノグリカンは、酸化ヒアルロン酸、酸化コンドロイチン硫酸、酸化コンドロイチン、酸化デルマタン硫酸、酸化ヘパラン硫酸、酸化ヘパリン及び酸化ケラタン硫酸からなる群から選択される請求項1に記載の生分解性医療用接着剤又はシーラント組成物。
- 前記酸化グリコサミノグリカンは、下記式によって計算した酸化度(%)が10乃至99.5%である請求項1に記載の生分解性医療用接着剤又はシーラント組成物。
- 前記第1成分は、2種類以上の酸化グリコサミノグリカンを含む請求項1に記載の生分解性医療用接着剤又はシーラント組成物。
- 前記2種類以上の酸化グリコサミノグリカンは、酸化ヒアルロン酸及び酸化コンドロイチン硫酸である請求項4に記載の生分解性医療用接着剤又はシーラント組成物。
- 前記酸化ヒアルロン酸の酸化度は、10〜40%であり、前記酸化コンドロイチン硫酸の酸化度は、10〜55%である請求項5に記載の生分解性医療用接着剤又はシーラント組成物。
- 前記ポリアミンは、ポリリジン、キトサン、アルブミン、プトレシン、カダベリン、スペルミジン、スペルミン、プロタミン及びPEI(Polyethylenimine)からなる群から選択される請求項1に記載の生分解性医療用接着剤又はシーラント組成物。
- 生体組織の接着、充填、塗布、癒着防止、創傷被覆及び止血からなる群から選択された医療用途を有する請求項1に記載の生分解性医療用接着剤又はシーラント組成物。
- アミン基を有する薬物をさらに含む請求項1に記載の生分解性医療用接着剤又はシーラント組成物。
- 請求項1に記載の生分解性医療用接着剤又はシーラント組成物を接着、充填、塗布、癒着防止、創傷被覆又は止血の必要な生体組織に適用する工程を含むことを特徴とする生体組織の接着、充填、塗布、癒着防止、創傷被覆又は止血方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0155722 | 2013-12-13 | ||
KR20130155722 | 2013-12-13 | ||
KR1020140089173A KR101664444B1 (ko) | 2013-12-13 | 2014-07-15 | 생분해성 의료용 접착제 또는 실란트 조성물 |
KR10-2014-0089173 | 2014-07-15 | ||
PCT/KR2014/012265 WO2015088275A1 (ko) | 2013-12-13 | 2014-12-12 | 생분해성 의료용 접착제 또는 실란트 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017500113A true JP2017500113A (ja) | 2017-01-05 |
JP6207745B2 JP6207745B2 (ja) | 2017-10-04 |
Family
ID=53516966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016538741A Active JP6207745B2 (ja) | 2013-12-13 | 2014-12-12 | 生分解性医療用接着剤又はシーラント組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10105465B2 (ja) |
EP (1) | EP3081236B1 (ja) |
JP (1) | JP6207745B2 (ja) |
KR (1) | KR101664444B1 (ja) |
CN (1) | CN106061518B (ja) |
AU (1) | AU2014360958B2 (ja) |
CA (1) | CA2933271C (ja) |
MX (1) | MX366143B (ja) |
RU (1) | RU2657836C1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020122007A1 (ja) * | 2018-12-14 | 2020-06-18 | 株式会社ビーエムジー | 2反応剤型のシート状組織接着補強材 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200030368A1 (en) * | 2016-07-29 | 2020-01-30 | Jawaharlal Nehru Centre For Advanced Scientific Research | A polymer network, method for production, and uses thereof |
KR20180040811A (ko) * | 2016-10-13 | 2018-04-23 | (주)웰빙해피팜 | 아민기가 포함된 생체 적합성 고분자로 가교시킨 히알루론산 조직수복용 생체 재료 및 이의 제조방법 |
KR101865781B1 (ko) * | 2016-11-10 | 2018-06-11 | (주)헵틸와이 | 산화 다당류 및 아민 변성 히알루론산을 포함하는 창상피복재용 히드로겔 및 그 제조방법 |
KR20200108020A (ko) * | 2018-01-12 | 2020-09-16 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | 지혈을 달성하기 위한 분말 |
CN108926736A (zh) * | 2018-08-20 | 2018-12-04 | 北京化工大学 | 多糖基组织粘合医用胶及其应用 |
KR101980063B1 (ko) * | 2019-01-25 | 2019-05-17 | 주식회사 휴메딕스 | 히알루론산을 포함하는 스펀지형 생분해성 지혈제 조성물 |
CN110279887B (zh) * | 2019-07-18 | 2021-12-14 | 王月玲 | 一种多用途光子冷凝胶及其制备方法 |
US11774338B2 (en) | 2020-10-21 | 2023-10-03 | Saudi Arabian Oil Company | Stokes-based method to estimate gelation time |
US11408809B2 (en) | 2020-10-21 | 2022-08-09 | Saudi Arabian Oil Company | Stuck-ball method to delineate gelation time |
WO2023221977A1 (zh) * | 2022-05-18 | 2023-11-23 | 朱小丰 | 一种硫酸软骨素生物多胺复合物、其制备方法及用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008067655A1 (en) * | 2006-12-05 | 2008-06-12 | Q6 Biomaterials Inc. | Biocompatible hydrogel-based scaffolds |
JP2009507110A (ja) * | 2005-09-09 | 2009-02-19 | オタワ ヘルス リサーチ インスティテュート | 相互侵入ネットワーク、およびそれに関連する方法および組成物 |
JP2013513671A (ja) * | 2009-12-11 | 2013-04-22 | コンティプロ ファーマ アクチオヴァ スポレチノスト | ヒアルロン酸の酸化誘導体,その調製方法及びその修飾方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9402529D0 (sv) | 1994-07-19 | 1994-07-19 | Astra Ab | Anti-adherensmedel |
EP1152013B1 (en) | 1998-11-10 | 2008-04-23 | Netech Inc. | Functional chitosan derivative |
CA2484453A1 (en) | 2002-04-23 | 2003-11-06 | Netech Inc. | Medicinal compositions containing photocrosslinkable chitosan derivative |
ZA200502606B (en) | 2002-09-25 | 2010-07-28 | Univ Johns Hopkins | Cross-linked polymer matrices, and methods of making and using same |
JP2006347883A (ja) * | 2003-09-08 | 2006-12-28 | Neetec:Kk | 糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物 |
KR100588614B1 (ko) | 2003-11-10 | 2006-06-13 | 주식회사 바이오레인 | 기포를 포함하는 유착방지제 |
BE1015863A6 (nl) | 2004-01-19 | 2005-10-04 | Huybrechts Lucas | Anticariogene proteinen & peptiden & sacchariden. |
US8431114B2 (en) * | 2004-10-07 | 2013-04-30 | Actamax Surgical Materials, Llc | Polysaccharide-based polymer tissue adhesive for medical use |
WO2008066182A1 (en) | 2006-11-30 | 2008-06-05 | Bmg Incorporated | Self-degradable adhesive for medical use of two-component reactant system comprising powder-liquid or powder-powder |
KR20070100230A (ko) | 2007-04-05 | 2007-10-10 | 베이코 테크 리미티드 | 히알루론산으로 코팅된 골 임플란트 장치 |
FR2919189A1 (fr) * | 2007-07-26 | 2009-01-30 | Cyclopharma Sa Lab | Nouvelles compositions a base de polyosides greffes par des composes polyamines ou polysoufres. |
US8426492B2 (en) * | 2007-11-14 | 2013-04-23 | Actamax Surgical Materials, Llc | Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use |
CN102883715B (zh) | 2008-04-24 | 2014-11-12 | 麦德托尼克公司 | 包含壳聚糖的保护性组合物 |
KR101309566B1 (ko) | 2010-12-10 | 2013-09-17 | 포항공과대학교 산학협력단 | 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법 |
-
2014
- 2014-07-15 KR KR1020140089173A patent/KR101664444B1/ko active IP Right Grant
- 2014-12-12 RU RU2016128376A patent/RU2657836C1/ru active
- 2014-12-12 AU AU2014360958A patent/AU2014360958B2/en active Active
- 2014-12-12 CN CN201480067775.9A patent/CN106061518B/zh active Active
- 2014-12-12 EP EP14870365.5A patent/EP3081236B1/en active Active
- 2014-12-12 JP JP2016538741A patent/JP6207745B2/ja active Active
- 2014-12-12 MX MX2016007688A patent/MX366143B/es active IP Right Grant
- 2014-12-12 US US15/102,406 patent/US10105465B2/en active Active
- 2014-12-12 CA CA2933271A patent/CA2933271C/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507110A (ja) * | 2005-09-09 | 2009-02-19 | オタワ ヘルス リサーチ インスティテュート | 相互侵入ネットワーク、およびそれに関連する方法および組成物 |
WO2008067655A1 (en) * | 2006-12-05 | 2008-06-12 | Q6 Biomaterials Inc. | Biocompatible hydrogel-based scaffolds |
JP2013513671A (ja) * | 2009-12-11 | 2013-04-22 | コンティプロ ファーマ アクチオヴァ スポレチノスト | ヒアルロン酸の酸化誘導体,その調製方法及びその修飾方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020122007A1 (ja) * | 2018-12-14 | 2020-06-18 | 株式会社ビーエムジー | 2反応剤型のシート状組織接着補強材 |
Also Published As
Publication number | Publication date |
---|---|
EP3081236A4 (en) | 2017-08-16 |
CA2933271C (en) | 2018-10-30 |
JP6207745B2 (ja) | 2017-10-04 |
KR101664444B1 (ko) | 2016-10-12 |
EP3081236A1 (en) | 2016-10-19 |
EP3081236B1 (en) | 2018-12-12 |
AU2014360958A1 (en) | 2016-07-14 |
US10105465B2 (en) | 2018-10-23 |
MX366143B (es) | 2019-06-28 |
RU2657836C1 (ru) | 2018-06-15 |
MX2016007688A (es) | 2016-12-16 |
AU2014360958B2 (en) | 2017-05-04 |
CN106061518A (zh) | 2016-10-26 |
US20160317702A1 (en) | 2016-11-03 |
CN106061518B (zh) | 2020-10-16 |
KR20150069992A (ko) | 2015-06-24 |
CA2933271A1 (en) | 2015-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6207745B2 (ja) | 生分解性医療用接着剤又はシーラント組成物 | |
Pourshahrestani et al. | Polymeric hydrogel systems as emerging biomaterial platforms to enable hemostasis and wound healing | |
JP4571693B2 (ja) | 自己分解性を有する粉体−液体及び粉体−粉体の2反応剤型の医療用接着剤 | |
JP4092512B2 (ja) | 自己分解性を有する医療用2液反応型接着剤、及び医療用樹脂 | |
Wei et al. | Mussel-inspired injectable hydrogel adhesive formed under mild conditions features near-native tissue properties | |
JP6017646B2 (ja) | 医療用ヒドロゲル組織接着剤 | |
EP3815697B1 (en) | Two-component hemostatic composition and method of manufacturing same | |
TW200824726A (en) | Rapidly acting dry sealant and methods for use and manufacture | |
WO2018079538A1 (ja) | 止血材 | |
JP2012523289A (ja) | 減少した分解時間を有するハイドロゲル組織接着剤 | |
US20190083676A1 (en) | Composite bioadhesive sealant | |
US20230285577A1 (en) | Polysaccharide derivative, polysaccharide derivative-drug conjugate, and method for producing same | |
WO2015088275A1 (ko) | 생분해성 의료용 접착제 또는 실란트 조성물 | |
ES2544962T3 (es) | Composiciones proteicas biocompatibles de fase invertible | |
ES2767878T3 (es) | Composiciones proteináceas de fase invertible biocompatibles y procedimientos para producir y usar las mismas | |
Yadav et al. | Polymer-based biomaterials and their applications in tissue adhesives | |
Choi et al. | Immediately activating hemostatic cellulose sealants for uncontrolled hemorrhage | |
WO2024123809A1 (en) | Flowable chitosan bioadhesive hemostatic compositions that resist dissolution | |
JP2023161851A (ja) | 接着剤、創傷被覆材、癒着防止材、止血材、シーラント、及び噴霧キット |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160610 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170404 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170703 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170710 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170808 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170905 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6207745 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |